169 related articles for article (PubMed ID: 32499442)
21. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
[TBL] [Abstract][Full Text] [Related]
22. Point mutations of the mTOR-RHEB pathway in renal cell carcinoma.
Ghosh AP; Marshall CB; Coric T; Shim EH; Kirkman R; Ballestas ME; Ikura M; Bjornsti MA; Sudarshan S
Oncotarget; 2015 Jul; 6(20):17895-910. PubMed ID: 26255626
[TBL] [Abstract][Full Text] [Related]
23. Downregulation of BAG‑1 in T47D cells promotes resistance to tamoxifen via activation of the PI3K/Akt/mTOR signaling pathway.
Lu S; Du Y; Cui F; Feng X; Ma Y; Liu H
Oncol Rep; 2019 Mar; 41(3):1901-1910. PubMed ID: 30747221
[TBL] [Abstract][Full Text] [Related]
24. Stress-induced mutagenesis and complex adaptation.
Ram Y; Hadany L
Proc Biol Sci; 2014 Oct; 281(1792):. PubMed ID: 25143032
[TBL] [Abstract][Full Text] [Related]
25. PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma.
Roldan-Romero JM; Beuselinck B; Santos M; Rodriguez-Moreno JF; Lanillos J; Calsina B; Gutierrez A; Tang K; Lainez N; Puente J; Castellano D; Esteban E; Climent MA; Arranz JA; Albersen M; Oudard S; Couchy G; Caleiras E; Montero-Conde C; Cascón A; Robledo M; Rodríguez-Antona C; García-Donas J;
Int J Cancer; 2020 Mar; 146(5):1435-1444. PubMed ID: 31335987
[TBL] [Abstract][Full Text] [Related]
26. mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy.
Tian T; Li X; Zhang J
Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30754640
[TBL] [Abstract][Full Text] [Related]
27. MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1.
Xu S; Fu GB; Tao Z; OuYang J; Kong F; Jiang BH; Wan X; Chen K
Oncotarget; 2015 Sep; 6(28):26457-71. PubMed ID: 26238185
[TBL] [Abstract][Full Text] [Related]
28. Changing mutational and adaptive landscapes and the genesis of cancer.
Liggett LA; DeGregori J
Biochim Biophys Acta Rev Cancer; 2017 Apr; 1867(2):84-94. PubMed ID: 28167050
[TBL] [Abstract][Full Text] [Related]
29. Mammalian target of rapamycin as a therapeutic target in oncology.
Abraham RT; Eng CH
Expert Opin Ther Targets; 2008 Feb; 12(2):209-22. PubMed ID: 18208369
[TBL] [Abstract][Full Text] [Related]
30. The mTOR signaling pathway in pediatric neuroblastoma.
Mei H; Wang Y; Lin Z; Tong Q
Pediatr Hematol Oncol; 2013 Oct; 30(7):605-15. PubMed ID: 23697980
[TBL] [Abstract][Full Text] [Related]
31. Chronic TGF-β exposure drives stabilized EMT, tumor stemness, and cancer drug resistance with vulnerability to bitopic mTOR inhibition.
Katsuno Y; Meyer DS; Zhang Z; Shokat KM; Akhurst RJ; Miyazono K; Derynck R
Sci Signal; 2019 Feb; 12(570):. PubMed ID: 30808819
[TBL] [Abstract][Full Text] [Related]
32. MTOR mutations in the crosshairs of targeted therapy.
Rejto PA; Abraham RT
Cancer Discov; 2014 May; 4(5):513-5. PubMed ID: 24795009
[TBL] [Abstract][Full Text] [Related]
33. ETV7 is an essential component of a rapamycin-insensitive mTOR complex in cancer.
Harwood FC; Klein Geltink RI; O'Hara BP; Cardone M; Janke L; Finkelstein D; Entin I; Paul L; Houghton PJ; Grosveld GC
Sci Adv; 2018 Sep; 4(9):eaar3938. PubMed ID: 30258985
[TBL] [Abstract][Full Text] [Related]
34. Recent development in targeting PI3K-Akt-mTOR signaling for anticancer therapeutic strategies.
Qazi AK; Hussain A; Hamid A; Qurishi Y; Majeed R; Ahmad M; Najar RA; Bhat JA; Singh SK; Zargar MA; Ali S; Saxena AK
Anticancer Agents Med Chem; 2013 Dec; 13(10):1552-64. PubMed ID: 23438828
[TBL] [Abstract][Full Text] [Related]
35. Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex.
Gkountakos A; Pilotto S; Mafficini A; Vicentini C; Simbolo M; Milella M; Tortora G; Scarpa A; Bria E; Corbo V
Carcinogenesis; 2018 Jul; 39(8):971-980. PubMed ID: 29955840
[TBL] [Abstract][Full Text] [Related]
36. Current development of mTOR inhibitors as anticancer agents.
Faivre S; Kroemer G; Raymond E
Nat Rev Drug Discov; 2006 Aug; 5(8):671-88. PubMed ID: 16883305
[TBL] [Abstract][Full Text] [Related]
37. Dual modulation of MCL-1 and mTOR determines the response to sunitinib.
Elgendy M; Abdel-Aziz AK; Renne SL; Bornaghi V; Procopio G; Colecchia M; Kanesvaran R; Toh CK; Bossi D; Pallavicini I; Perez-Gracia JL; Lozano MD; Giandomenico V; Mercurio C; Lanfrancone L; Fazio N; Nole F; Teh BT; Renne G; Minucci S
J Clin Invest; 2017 Jan; 127(1):153-168. PubMed ID: 27893461
[TBL] [Abstract][Full Text] [Related]
38. Targeting the mTOR pathway in tumor malignancy.
Cheng H; Walls M; Baxi SM; Yin MJ
Curr Cancer Drug Targets; 2013 Mar; 13(3):267-77. PubMed ID: 23297825
[TBL] [Abstract][Full Text] [Related]
39. The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma.
Pollutri D; Patrizi C; Marinelli S; Giovannini C; Trombetta E; Giannone FA; Baldassarre M; Quarta S; Vandewynckel YP; Vandierendonck A; Van Vlierberghe H; Porretti L; Negrini M; Bolondi L; Gramantieri L; Fornari F
Cell Death Dis; 2018 Jan; 9(1):4. PubMed ID: 29305580
[TBL] [Abstract][Full Text] [Related]
40. [Stress-induced cellular adaptive mutagenesis].
Zhu L; Li Q
Yi Chuan; 2014 Apr; 36(4):327-35. PubMed ID: 24846977
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
